ArticleScientific reports2025
Impact of pesticide diazinon on gastric cancer cell lines and the alteration of cholinergic and serotonergic pathway genes affecting cell proliferation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HTR3A Receptor Signaling in Human Disease: From Bioelectrical Regulation to Therapeutic Targeting.Molecular neurobiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diazinon (DZN) is an organophosphorus (OP) pesticide implicated in carcinogenesis. Its primary mechanism of action is inhibition of acetylcholinesterase (AChE). We evaluated the impact of low-dose DZN on two gastric cancer (GC) cell lines (AGS, MKN-45), focusing on cholinergic and serotonergic signaling. Proliferation-stimulatory concentrations were identified by MTT assay (0.1 µM for AGS, 0.01 µM for MKN-45). Scratch assays demonstrated enhanced migration at low doses but suppression at high dose. AO/EB staining confirmed reduced viability with increased apoptosis at high dose. Cell cycle analysis further revealed S-phase accumulation. qRT-PCR demonstrated upregulation of CHRM3, SLC18A3, HTR2A/B, SLC6A4, BCL2 and PCNA, with concomitant downregulation of ACHE, MAOA and BAX in both lines; HTR3A and HTR7 were selectively elevated in AGS cells. Complementary in silico analysis of gastric tumor RNA-seq data (GSE113255) confirmed differential expression of neurotransmission-related genes and enrichment of cholinergic/serotonergic pathways. Collectively, these data indicate that submicromolar DZN promotes proliferation and suppresses apoptosis of GC cells by perturbing neuronal signaling networks. Our findings provide novel evidence linking environmental OP exposure to dysregulated neurotransmitter pathways in gastric carcinogenesis and highlight neuronal signaling components as potential therapeutic or preventive targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.